Close
Back to NEPT Stock Lookup

Neptune Wellness Solutions (NEPT) – Globe Newswire

May 5, 2021 10:01 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the
Apr 28, 2021 03:00 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the
Apr 21, 2021 05:00 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against XL Fleet Corp., Bellus Health, Neptune Wellness, and Sequential Brands and Encourages Investors to Cont
Apr 21, 2021 03:01 PM NEPT ALERT: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Neptune Wellness Solutions Inc. – NEPT
Apr 14, 2021 06:00 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the
Apr 7, 2021 07:00 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against XL Fleet Corp., Bellus Health, Neptune Wellness, and Sequential Brands and Encourages Investors to Cont
Mar 31, 2021 07:00 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Plug Power, XL Fleet Corp., Bellus Health, and Neptune Wellness and Encourages Investors to Contact the
Mar 24, 2021 08:00 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the
Nov 16, 2020 06:55 AM Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2021
Oct 1, 2020 04:30 PM Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Option and Equity Incentive Plans, Adoption of Amended & Restated General
Sep 29, 2020 06:55 AM Acasti Announces Review Process of Strategic Alternatives
Sep 16, 2020 06:55 AM Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer
Sep 11, 2020 07:00 AM Acasti Announces Filing and Mailing of Information Circular and Change in Record Date
Aug 31, 2020 07:00 AM Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia
Aug 13, 2020 08:30 AM Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021
Jul 31, 2020 07:55 AM Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020
Jun 29, 2020 09:45 AM Acasti Pharma Provides Fiscal 2020 Year-End Business Update
Jun 19, 2020 08:00 AM Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package
Apr 30, 2020 08:30 AM Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA
Apr 20, 2020 08:30 AM Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada
Apr 1, 2020 08:30 AM Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June
Mar 11, 2020 08:00 AM Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico
Feb 28, 2020 05:00 PM Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements
Feb 14, 2020 08:00 AM Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020
Feb 13, 2020 09:00 AM Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call
Feb 10, 2020 07:00 AM Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre
Jan 13, 2020 06:00 AM Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre
Dec 23, 2019 08:31 PM Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre
Nov 26, 2019 07:55 AM Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia
Nov 18, 2019 08:38 AM Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre’s Novel Mechanism of Action in Diabetes
Nov 13, 2019 07:55 AM Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2020
Nov 7, 2019 08:30 AM Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal
Nov 6, 2019 09:00 AM Acasti Pharma Schedules Second Quarter Fiscal 2020 Conference Call
Nov 4, 2019 09:04 AM Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for CaPre®
Oct 1, 2019 09:00 AM Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
Sep 30, 2019 08:35 AM Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020
Sep 9, 2019 08:30 AM Acasti Pharma Receives Funding from the Government of Canada to Expand Production Capacity
Sep 4, 2019 09:00 AM Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9th
Aug 28, 2019 04:05 PM Acasti Pharma Announces the Election of Its Directors, Amendments to Its Stock Option and Equity Incentive Plans and Other Related Matters Approved at Its AGM
Aug 14, 2019 08:00 AM Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2020
Aug 9, 2019 08:00 AM Acasti Pharma Co-Founder, Chief Operating and Scientific Officer to Participate on Lipid Panel at the 2019 BTIG Biotechnology Conference
Aug 7, 2019 08:00 AM Acasti Pharma Schedules First Quarter Fiscal 2020 Conference Call
Jul 25, 2019 03:42 PM Acasti Pharma Comments on Trading Activity and Reaffirms No Plans to Raise Capital

Back to NEPT Stock Lookup